Adc Therapeutics SA (NYSE: ADCT) has seen a rise in its stock price by 2.01 in relation to its previous close of 1.99. However, the company has experienced a -4.69% decline in its stock price over the last five trading sessions. seekingalpha.com reported 2024-12-12 that Initial positive results released from the phase 1b study, using ZYNLONTA + COLUMVI for the treatment of patients with 2nd-line relapsed/refractory DLBCL. Additional results from the phase 1b study, using ZYNLONTA + COLUMVI for the treatment of patients with 2nd-line relapsed/refractory DLBCL, to be released in the 1st half of 2025. The seven major Diffuse Large B-cell Lymphoma markets are expected to reach $5.25 billion by 2034.
Is It Worth Investing in Adc Therapeutics SA (NYSE: ADCT) Right Now?
Moreover, the 36-month beta value for ADCT is 1.55. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ADCT is 77.58M and currently, short sellers hold a 3.89% of that float. On December 25, 2024, ADCT’s average trading volume was 800.75K shares.
ADCT’s Market Performance
ADCT stock saw an increase of -4.69% in the past week, with a monthly gain of 2.01% and a quarterly increase of -33.66%. The volatility ratio for the week is 10.67%, and the volatility levels for the last 30 days are 16.57% for Adc Therapeutics SA (ADCT). The simple moving average for the last 20 days is -10.43% for ADCT stock, with a simple moving average of -39.20% for the last 200 days.
Analysts’ Opinion of ADCT
Many brokerage firms have already submitted their reports for ADCT stocks, with Stephens repeating the rating for ADCT by listing it as a “Overweight.” The predicted price for ADCT in the upcoming period, according to Stephens is $6 based on the research report published on November 08, 2024 of the current year 2024.
Guggenheim gave a rating of “Buy” to ADCT, setting the target price at $11 in the report published on March 28th of the current year.
ADCT Trading at -21.18% from the 50-Day Moving Average
After a stumble in the market that brought ADCT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -66.39% of loss for the given period.
Volatility was left at 16.57%, however, over the last 30 days, the volatility rate increased by 10.67%. Over the last 50 days, in opposition, the stock is trading -33.66% lower at present.
During the last 5 trading sessions, ADCT fell by -4.69%, which changed the moving average for the period of 200-days by -54.38% in comparison to the 20-day moving average, which settled at $2.2700. In addition, Adc Therapeutics SA saw 22.29% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADCT starting from Redmile Group, LLC, who purchase 100,000 shares at the price of $3.04 back on Dec 11 ’24. After this action, Redmile Group, LLC now owns 15,666,731 shares of Adc Therapeutics SA, valued at $304,500 using the latest closing price.
Redmile Group, LLC, the 10% Owner of Adc Therapeutics SA, purchase 100,000 shares at $3.04 during a trade that took place back on Dec 11 ’24, which means that Redmile Group, LLC is holding 13,145,712 shares at $304,500 based on the most recent closing price.
Stock Fundamentals for ADCT
Current profitability levels for the company are sitting at:
- -1.97 for the present operating margin
- 0.89 for the gross margin
The net margin for Adc Therapeutics SA stands at -3.02. The total capital return value is set at -0.49. Equity return is now at value -705.53, with -52.00 for asset returns.
Based on Adc Therapeutics SA (ADCT), the company’s capital structure generated 2.08 points at debt to capital in total, while cash flow to debt ratio is standing at -0.4. The debt to equity ratio resting at -1.93. The interest coverage ratio of the stock is -2.7.
Currently, EBITDA for the company is -146.76 million with net debt to EBITDA at -0.49. When we switch over and look at the enterprise to sales, we see a ratio of 3.58. The receivables turnover for the company is 2.92for trailing twelve months and the total asset turnover is 0.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.92.
Conclusion
To wrap up, the performance of Adc Therapeutics SA (ADCT) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
